Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Organogenesis Holdings (ORGO) EBIAT (2016 - 2025)

Organogenesis Holdings has reported EBIAT over the past 10 years, most recently at $43.7 million for Q4 2025.

  • Quarterly results put EBIAT at $43.7 million for Q4 2025, up 469.53% from a year ago — trailing twelve months through Dec 2025 was $37.0 million (up 4201.05% YoY), and the annual figure for FY2025 was $37.0 million, up 4201.05%.
  • EBIAT for Q4 2025 was $43.7 million at Organogenesis Holdings, up from $21.6 million in the prior quarter.
  • Over the last five years, EBIAT for ORGO hit a ceiling of $51.0 million in Q4 2021 and a floor of -$18.8 million in Q1 2025.
  • Median EBIAT over the past 5 years was $6.4 million (2022), compared with a mean of $7.6 million.
  • Biggest five-year swings in EBIAT: skyrocketed 1450.88% in 2024 and later crashed 797.29% in 2025.
  • Organogenesis Holdings' EBIAT stood at $51.0 million in 2021, then tumbled by 85.32% to $7.5 million in 2022, then tumbled by 107.59% to -$568000.0 in 2023, then skyrocketed by 1450.88% to $7.7 million in 2024, then skyrocketed by 469.53% to $43.7 million in 2025.
  • The last three reported values for EBIAT were $43.7 million (Q4 2025), $21.6 million (Q3 2025), and -$9.4 million (Q2 2025) per Business Quant data.